Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine/Glycopyrrolate for NMB Reversal
NCT03116997Phase 3Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2017
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
A Phase 3 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2017; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03116997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116997.